|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/08/19 Sangamo Therapeutics, Inc 10-Q 3/31/19 57:7.3M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 737K
2: EX-10.3 Material Contract HTML 32K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 26K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 26K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
12: R1 Document and Entity Information HTML 44K
13: R2 Condensed Consolidated Balance Sheets HTML 123K
14: R3 Condensed Consolidated Statements of Operations HTML 54K
15: R4 Condensed Consolidated Statements of Comprehensive HTML 42K
Loss
16: R5 Condensed Consolidated Statements of Stockholders' HTML 62K
Equity
17: R6 Condensed Consolidated Statements of Cash Flows HTML 109K
18: R7 Organization, Basis of Presentation and Summary of HTML 127K
Significant Accounting Policies
19: R8 Fair Value Measurements HTML 240K
20: R9 Marketable Securities HTML 178K
21: R10 Basic and Diluted Net Loss Per Share HTML 22K
22: R11 Major Customers, Partnerships and Strategic HTML 87K
Alliances
23: R12 Income Taxes HTML 22K
24: R13 Stock-Based Compensation HTML 39K
25: R14 Commitments and Contingencies HTML 60K
26: R15 Stockholders' Equity HTML 24K
27: R16 Acquisition of Txcell S.A. HTML 83K
28: R17 Subsequent Events HTML 21K
29: R18 Organization, Basis of Presentation and Summary of HTML 151K
Significant Accounting Policies (Policies)
30: R19 Organization, Basis of Presentation and Summary of HTML 86K
Significant Accounting Policies (Tables)
31: R20 Fair Value Measurements (Tables) HTML 238K
32: R21 Marketable Securities (Tables) HTML 176K
33: R22 Major Customers, Partnerships and Strategic HTML 43K
Alliances (Tables)
34: R23 Stock-Based Compensation (Tables) HTML 39K
35: R24 Commitments and Contingencies (Tables) HTML 52K
36: R25 Acquisition of Txcell S.A. (Tables) HTML 71K
37: R26 Organization, Basis of Presentation and Summary of HTML 78K
Significant Accounting Policies - Additional
Information (Detail)
38: R27 Organization, Basis of Presentation and Summary of HTML 52K
Significant Accounting Policies - Impact of
Adoption of ASC on Condensed Consolidated Balance
Sheet (Details)
39: R28 Fair Value Measurements - Summary of Fair Value HTML 66K
Measurements of Cash Equivalents,
Available-for-Sale Marketable Securities and Free
Share Asset/Liability (Detail)
40: R29 Fair Value Measurements - Additional Information HTML 28K
(Detail)
41: R30 Fair Value Measurements - Summary of Estimated HTML 44K
Fair Value of Free Shares Valuation Assumptions
(Detail)
42: R31 Marketable Securities - Summary of Cash HTML 58K
Equivalents and Available-for-Sale Securities
(Detail)
43: R32 Marketable Securities - Additional Information HTML 25K
(Detail)
44: R33 Basic and Diluted Net Loss Per Share - Additional HTML 21K
Information (Detail)
45: R34 Major Customers, Partnerships and Strategic HTML 161K
Alliances - Additional Information (Detail)
46: R35 Major Customers, Partnerships and Strategic HTML 28K
Alliances - Revenues Recognized under Agreement
(Detail)
47: R36 Stock-Based Compensation - Stock-Based HTML 27K
Compensation Expense (Detail)
48: R37 Commitments and Contingencies - Additional HTML 89K
Information (Detail)
49: R38 Commitments and Contingencies - Summary of HTML 45K
Maturities of Operating Lease Liabilities (Detail)
50: R39 Stockholders' Equity - Additional Information HTML 32K
(Detail)
51: R40 Acquisition of Txcell S.A. - Additional HTML 77K
Information (Detail)
52: R41 Acquisition of Txcell S.A. - Summary of Estimated HTML 58K
Fair Value of Net Assets Acquired (Detail)
53: R42 Acquisition of Txcell S.A. - Summary of HTML 36K
Non-controlling Interest (Detail)
54: R43 Subsequent Events - Additional Information HTML 32K
(Detail)
56: XML IDEA XML File -- Filing Summary XML 101K
55: EXCEL IDEA Workbook of Financial Reports XLSX 67K
6: EX-101.INS XBRL Instance -- sgmo-20190331 XML 2.09M
8: EX-101.CAL XBRL Calculations -- sgmo-20190331_cal XML 162K
9: EX-101.DEF XBRL Definitions -- sgmo-20190331_def XML 530K
10: EX-101.LAB XBRL Labels -- sgmo-20190331_lab XML 1.01M
11: EX-101.PRE XBRL Presentations -- sgmo-20190331_pre XML 755K
7: EX-101.SCH XBRL Schema -- sgmo-20190331 XSD 152K
57: ZIP XBRL Zipped Folder -- 0001564590-19-017255-xbrl Zip 142K
[*] = Certain confidential information contained in this document, marked by brackets, is omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
Exhibit 10.3
Amendment No. 1 to Agreement
(“Amendment No. 1”)
|
Amendment No. 1 Date: |
|
Date of Last Signature |
|
|
|
|
|
Name of Original Agreement: |
|
Research Collaboration and License Agreement (the “Agreement”) |
|
|
|
|
|
Effective Date of Original Agreement: |
|
28 December 2017 (“Effective Date”) |
|
|
|
|
|
Parties: |
|
Pfizer Inc. (“Pfizer”) and Sangamo Therapeutics, Inc. (“Sangamo”). Individually a “Party” and collectively the “Parties.” |
|
|
|
|
|
Dates of Previous Amendment(s): |
|
None |
WHEREAS, the Parties desire to amend the Research Plan of the Agreement,
NOW, THEREFORE, in order to accommodate the desired amendment(s), the Parties hereby agree as follows:
|
1. |
Defined Terms. Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Agreement. |
|
2. |
Amendment(s) to the Agreement. |
Section 4 of Exhibit B, Research Plan is amended to include the following as Work Package 4:
Work package 4: [*]
|
3. |
The ZFP-TFs provided by Sangamo for use in the [*] study are experimental and have not been [*]. |
|
4. |
The ZFP-TFs provided by Sangamo for use in the [*] study have not been [*]. |
|
6. |
Counterparts. This Amendment No. 1 may be executed in any number of counterparts, each of which shall be an original instrument and all of which, when taken together, shall constitute one and the same agreement. |
SIGNATURES IMMEDIATELY FOLLOWING ON NEXT PAGE
IN WITNESS WHEREOF, the duly authorized representatives of Pfizer and Sangamo have executed this Amendment No. 1 as of the Amendment No. 1 Date.
|
Pfizer Inc. |
|
Sangamo Therapeutics, Inc. |
||||
|
|
|
|
||||
|
By: |
|
/s/ Seng H. Cheng |
|
By: |
|
/s/ Alexander macrae |
|
|
|
|
|
|
|
|
|
Print Name: |
|
|
Print Name: |
|
||
|
|
|
|
|
|
|
|
|
Title: |
|
SVP & CSO |
|
Title: |
|
CEO |
|
|
|
|
|
|
|
|
|
Date: |
|
|
Date: |
|
Mar 14, 2019 |
|
|
|
|
(Duly authorized) |
|
|
|
(Duly authorized) |
[*] = Certain confidential information contained in this document, marked by brackets, is omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/8/19 | 8-K | ||
| For Period end: | 3/31/19 | |||
| 3/21/19 | 8-K | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/13/24 Sangamo Therapeutics, Inc. 10-K 12/31/23 96:41M Workiva Inc Wde… FA01/FA 2/23/23 Sangamo Therapeutics, Inc. 10-K 12/31/22 87:116M Workiva Inc Wde… FA01/FA 2/24/22 Sangamo Therapeutics, Inc. 10-K 12/31/21 94:51M Workiva Inc Wde… FA01/FA 2/24/21 Sangamo Therapeutics, Inc. 10-K 12/31/20 89:14M Workiva Inc Wde… FA01/FA |